SCHEMBL3607295

SCHEMBL3607295

CC(C)(C)OC(=O)N[C@H](CN)COc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.50
MTNR1A P48039 3/20 0.47
MTNR1B P49286 3/20 0.47
HDAC8 Q9BY41 4/20 0.46
HDAC3 O15379 3/20 0.46
HDAC4 P56524 3/20 0.46
HDAC1 Q13547 3/20 0.46
HDAC7 Q8WUI4 3/20 0.46
HDAC2 Q92769 3/20 0.46
HDAC10 Q969S8 3/20 0.46
HDAC11 Q96DB2 3/20 0.46
HDAC6 Q9UBN7 3/20 0.46
HDAC9 Q9UKV0 3/20 0.46
HDAC5 Q9UQL6 3/20 0.46
PPARA Q07869 2/20 0.44
SYK P43405 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
AAK1 Q2M2I8 3/20 0.44
MMP13 P45452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607294 1.00 ATM (0.50) ATMMTNR1AMTNR1BHDAC8HDAC3
SCHEMBL19382648 0.88 ATM (0.51) ATMMTNR1AMTNR1BHDAC8HDAC3
SCHEMBL30639552 0.85 ATM (0.65) ATMHDAC8HDAC3HDAC4HDAC1
SCHEMBL3611690 0.82 ATM (0.46) ATMMTNR1AMTNR1BHDAC8HDAC3
SCHEMBL3611698 0.82 ATM (0.46) ATMMTNR1AMTNR1BHDAC8HDAC3
SCHEMBL3611694 0.82 ATM (0.46) ATMMTNR1AMTNR1BHDAC8HDAC3
SCHEMBL507001 0.82 MTNR1A (0.66) ATMMTNR1AMTNR1BPPARACTSS
SCHEMBL507002 0.82 MTNR1A (0.66) ATMMTNR1AMTNR1BPPARACTSS
SCHEMBL30241501 0.82 MTNR1A (0.66) ATMMTNR1AMTNR1BPPARACTSS
SCHEMBL1000339 0.82 PPARA (0.63) ATMPPARASYKCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487108-B2 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-07-16 US disclosed
US-8487108-B2 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-07-16 US disclosed
US-8487108-B2 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-07-16 US disclosed
EP-1966139-B1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS INC (US) 2011-12-21 EP disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 US disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 US disclosed
EP-1966139-A1 ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2008-09-10 EP disclosed
WO-2007070201-A1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-06-21 WO disclosed
WO-2007070201-A1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048636-A1 Aspartic Protease Inhibitors DNPEP, PEPD, SERPINB1 ATM 3337/4885MTNR1A 2923/4885MTNR1B 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.